Allogene Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Allogene Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2023.
  • Allogene Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$71.8M, a 13.9% decline year-over-year.
  • Allogene Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$298M, a 12.2% increase year-over-year.
  • Allogene Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$328M, a 2.32% increase from 2022.
  • Allogene Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$336M, a 86.2% decline from 2021.
  • Allogene Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$180M, a 30.2% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$328M +$7.8M +2.32% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-14
2022 -$336M -$155M -86.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 -$180M +$78.1M +30.2% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-14
2020 -$258M -$56.2M -27.8% Jan 1, 2020 Dec 31, 2020 10-K/A 2024-03-14
2019 -$202M -$9.17M -4.75% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-23
2018 -$193M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.